Huntington's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Huntington's Disease, including details on genetics, causes, symptoms, treatment.

Volume 1 (2005), Issue 6 (June)

1. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model.
   Neurosci Res, 52(3): 243-9. [Abstract] [Full-text]
2. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease.
   J Neurochem, 93(6): 1361-70. [Abstract] [Full-text]
3. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
   J Neurochem, 93(5): 1057-68. [Abstract] [Full-text]
4. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.
   Mov Disord, 20(6): 674-9. [Abstract] [Full-text]
5. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
   Brain Res, 1047(2): 148-58. [Abstract] [Full-text]
6. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.
   Biol Psychiatry, 57(12): 1583-9. [Abstract] [Full-text]
7. Monozygotic twins discordant for Huntington disease after 7 years.
   Arch Neurol, 62(6): 995-7. [Abstract] [Full-text]
8. Negotiating responsibility: case studies of reproductive decision-making and prenatal genetic testing in families facing Huntington disease.
   J Genet Couns, 14(3): 219-34. [Abstract] [Full-text]
9. Psychodynamic theory and counseling in predictive testing for Huntington's disease.
   J Genet Couns, 14(2): 99-107. [Abstract] [Full-text]
10. Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease.
    Pharmacol Res, 52(2): 140-50. [Abstract] [Full-text]
11. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery.
    Pharmacol Res, 52(2): 133-9. [Abstract] [Full-text]
12. Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
    Hum Mol Genet, 14(13): 1863-76. [Abstract] [Full-text]
13. The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease.
    J Neurol, 252(6): 642-7. [Abstract] [Full-text]

© 2005-2008 Huntington's Disease Research Today. All Rights Reserved.